Pediatrix Medical Group, Inc. (MD) Form 8-K — Oct 29, 2026
Pediatrix Medical Group (NYSE: MD) reported Q3 2026 net revenue of $501.4 million, up 1.7% year over year, with net income of $47.0 million ($0.59 per diluted share) and Adjusted EPS of $0.72, up from $0.67 a year ago. The quarter was mixed: volume and pricing performed ahead of management expectations, but GAAP net income fell from $71.7 million in Q3 2025 (which included a $20.9 million gain on divested businesses), and Adjusted EBITDA declined to $85.5 million from $87.3 million on higher expense growth relative to revenue. The company generated $117.7 million of operating cash flow, used $83.0 million on buybacks, and holds $311.9 million in cash against $578 million in total debt.
Key figures
- Eps
- 0.59
- Revenue
- 501400000
- Guidance
- Full year 2026 Adjusted EBITDA outlook of $290 million to $300 million
- Net Income
- 47000000
- Total Debt
- 578000000
- Total Assets
- 2139420000
- Cash Position
- 311900000
- Shares Outstanding
- 79700000
- Revolver capacity
- 450000000
- Senior notes 2030
- 400000000
- Nine month revenue
- 1470000000
- Adjusted eps q3 2025
- 0.67
- Adjusted eps q3 2026
- 0.72
- Term loan borrowings
- 178000000
- Nine month net income
- 116400000
- Adjusted ebitda q3 2025
- 87300000
- Adjusted ebitda q3 2026
- 85500000
- Share repurchases q3 2026
- 83000000
- Nine month adjusted ebitda
- 220100000
- Operating cash flow q3 2026
- 117700000
- Prior year net income q3 2025
- 71700000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.